US Said To Be Nudging OPEC+ To Avoid Big Output Cuts: Why It Matters For Biden And Democrats

The United States is nudging the Organization of the Petroleum Exporting Countries and its allies, known as the OPEC+ nations, to avoid significant oil output cuts when President Joe Bid

The United States is nudging the Organization of the Petroleum Exporting Countries and its allies, known as the OPEC+ nations, to avoid significant oil output cuts when President Joe Biden is seeking to prevent U.S. gasoline prices from rising, reported Reuters.

What Happened: Washington is arguing with OPEC+ that economic fundamentals don’t support an output cut, reported Reuters, citing sources.

Oil prices have been falling over the last four months, dragged by fears of a global recession after central banks worldwide tightened their policy rates aggressively to rein in inflation. However, prices soared over 3% on Monday after reports indicated the OPEC+ is likely to consider an output cut of over a million barrels per day in the fresh trading week.

Also Read: The Best Oil ETFs Of 2022

The United States Brent Oil Fund (NYSE: BNO) closed 3% higher on Tuesday, while the Vanguard Energy Index Fund ETF (NYSE: VDE) closed over 4%.

White House Press Secretary Karine Jean-Pierre said they would not comment on any OPEC action until the Organization acts. “In any event, we will continue to take steps to protect American consumers. Our focus — and it’s been very clear for the past several — several months — has been on taking every step to ensure markets are sufficiently supplied to meet the demand for a growing global economy,” she said.

Why It Matters: An increase in oil prices could potentially impact Democratic prospects during the Nov. 8 midterm congressional elections, the report said. OPEC+ had reduced its output by 100,000 barrels per day in September.

Read Next: Oil Jumps Over 3% As OPEC+ Meet Eyed: Analysts Say This Is The Bare Minimum Supply Cut For Markets To Care

 

Total
0
Shares
Related Posts
Read More

AbbVie Announced FDA Approved the Use of Imbruvica for the Treatment of Pediatric Patients One Year and Older With cGVHD After Failure of One or More Lines of Systemic Therapy

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

ABBV